Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study

C Wang, H Ahlstrom, S Ekholm, H Fagertun, M Hellstrom, A Hemmingsson, Stig Holtås, B Isberg, E Jonnson, M Lonnemark-Magnusson, S McGill, N O Wallengren, L Westman

Research output: Contribution to journalArticlepeer-review


PURPOSE: To assess the diagnostic efficacy, safety and tolerability of mangafodipir trisodium (MnDPDP, Teslascan) in MR imaging of the liver. MATERIAL AND METHODS: Eighty-two patients from 4 centres underwent MR imaging with pre-contrast sequences including T1-weighted SE and GRE, and T2-weighted turbo SE sequences. MnDPDP at a dose of 5 mumol/kg b.w. was administered by slow i.v. infusion, and 20-60 min after infusion the T1-weighted SE and GRE sequences were repeated. Diagnostic efficacy was evaluated by counting the number of lesions and by evaluating whether more information for lesion characterisation was available in post-contrast images. Safety and tolerability were assessed by recording adverse events and infusion-related discomfort. RESULTS: Significantly more lesions were found in MnDPDP-enhanced T1-weighted SE and GRE images than in unenhanced images of the same sequences. More lesions were also found in these images compared with T2-weighted images at a level of marginal significance. More information was obtained from MnDPDP-enhanced images in 40 cases. Mild to moderate adverse events were experienced by 17% of the patients. CONCLUSION: MnDPDP-enhanced images can improve lesion detection in the liver and are helpful for lesion characterisation. To obtain optimal diagnostic information of liver lesions T2-weighted images are also valuable. MnDPDP is a safe contrast agent for MR imaging of liver lesions.
Original languageEnglish
Pages (from-to)643-649
JournalActa Radiologica
Issue number4
Publication statusPublished - 1997

Subject classification (UKÄ)

  • Radiology, Nuclear Medicine and Medical Imaging


Dive into the research topics of 'Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study'. Together they form a unique fingerprint.

Cite this